Overview
TNDM market data
Price History
TNDM price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.04 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.51 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $9.98 – $29.65 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $1.3K · P/B 9.60 · P/S 1.28.
Company News
Shares of medical device companies are trading higher amid sympathy with Abbott Laboratories after that company reported better-than-expected Q2 financial results and raised its FY adjusted EPS guidance with its midpoint above estimates.Benzinga · Jul 16, 2026, 4:35 PM
Mizuho Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $20Benzinga · Jul 15, 2026, 6:35 PM
This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For TuesdayBenzinga · Jun 23, 2026, 1:50 PM
Deutsche Bank Initiates Coverage On Tandem Diabetes Care with Hold Rating, Announces Price Target of $15.5Benzinga · Jun 23, 2026, 1:30 PM
Tandem Diabetes Care Receives CE Mark For Expanded Indications Of Its Automated Insulin Delivery Systems In EuropeBenzinga · Jun 5, 2026, 12:35 PM
Tandem Diabetes Care shares are trading higher after Wells Fargo upgraded the stock from Equal-Weight to Overweight rating and raised its price target from $21 to $27.Benzinga · Jun 1, 2026, 2:53 PM
Wells Fargo Upgrades Tandem Diabetes Care to Overweight, Raises Price Target to $27Benzinga · Jun 1, 2026, 1:45 PM
Citigroup Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $17Benzinga · May 28, 2026, 8:09 PM
8-K filing — TANDEM DIABETES CARE INC (TNDM)SEC EDGAR · May 21, 2026, 8:10 PM
B of A Securities Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $25Benzinga · May 18, 2026, 6:05 PM